Insider · CIK 0001814304
Karen Lewis
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Jan 14, 2025, latest Jan 30, 2025.
In brief
Karen Lewis files SEC Form 4 as officer at APLS (Apellis Pharmaceuticals, Inc.). Since Jan 14, 2025, Karen Lewis has reported 0 open-market buys worth $0 and 4 open-market sells worth $147k, the latest filed on Jan 30, 2025.
A track record needs three past buys with six months of prices behind them; Karen Lewis has 0, so none is measured yet.
The newest scored trade: sold $11k of APLS on Jan 29, 2025, filed Jan 30, 2025, scored 30 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Apellis Pharmaceuticals, Inc. | $11k 364 shares | -1% | - | |
| 37Weak | Apellis Pharmaceuticals, Inc. | $53k 1,751 shares | -2% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $37k 1,241 shares | -3% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $46k 1,599 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | 364 0.00% of outstanding | $11k | Jan 29, 2025 | $137k |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | 1,751 0.00% of outstanding | $53k | Jan 22, 2025 | $84k |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | 1,241 0.00% of outstanding | $37k | Jan 17, 2025 | $47k |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | 1,627 0.00% of outstanding | $47k | Jan 13, 2025 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -364 | $29.52 | $11k | 70,251 | Jan 30, 2025 |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,751 | $30.43 | $53k | 70,615 | Jan 23, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,241 | $29.96 | $37k | 43,858 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +28,508 | $0.00 | $0 | 72,366 | Jan 21, 2025 |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,599 | $28.70 | $46k | 45,099 | Jan 14, 2025 |
Questions about Karen Lewis
Answered from the filings on this page, as of the latest one.
Is Karen Lewis buying or selling?
Not in the last 12 months. Karen Lewis's latest open-market trade on SEC Form 4 was sold $11k of APLS on Jan 29, 2025.
How did Karen Lewis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Karen Lewis has 0.
Where does Karen Lewis file Form 4?
Karen Lewis has filed Form 4 at APLS (Apellis Pharmaceuticals, Inc.) as Chief People Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.